On April 7, 2014, Sun Pharma agreed to buy generic drugmaker Ranbaxy Laboratories for $3.2 billion, betting it could fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo, and got Ranbaxy India-made drugs barred from the United States.
The all-share transaction, the biggest pharmaceutical sector deal in the Asia-Pacific region this year, will create the world's fifth-largest maker of generic drugs once they get the nod of the regulators.